Navigation Links
De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
Date:3/17/2013

>Une baisse de 24 % de la productivité au travail a été observée chez les patients nycturiques.  Il s'agit d'un chiffre plus élevé que celui rapporté pour l'hyperactivité vésicale (10-12 %)[4] et comparable à ceux d'autres maladies chroniques non urologiques telles que le RGO (25 %),[5] l'asthme sévère (21 %),[6] la BPCO (19 %)[7] et la constipation (34 %)[8]. De plus, la capacité des patients à exercer des activités dans la journée a été réduite de 34 %.[1]

Philip Van Kerrebroeck , MD, PhD, université de Maastricht a commenté les résultats de cette étude en déclarant : « La nycturie est un problème commun qui affecte environ un tiers des adultes, mais son fardeau est sous-estimé et souvent considéré comme étant moins grave que d'autres maladies chroniques en termes de qualité de vie et de coût pour la société.  Ces données montrent que tout comme d'autres maladies, la nycturie a un impact négatif sur  le sommeil, les performances dans la journée et la productivité au travail. Les patients qui en souffrent doivent consulter pour traiter spécifiquement cette maladie invalidante. »

La deuxième série de données présentées à l'EAU consistait en une analyse de données subjectives, rapportées par des patients, sur les symptômes qu'ils considèrent comme étant les plus gênants.  Les nombreux effets négatifs sur la qualité de vie associés à la nycturie avaient déjà été documentés, mais aucune étude jusque-là n'avait demandé aux patients d'expliquer pourquoi cette affe
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Elsevier Launches Evidence-Based, Collaborative Order Sets Solution
2. More evidence needed for scale up of mobile device technology in health
3. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
4. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
5. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
6. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
7. More evidence for longevity pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Market ... formed a strategic alliance with Designing Gig LLC to ... clients. , “Forging this alliance with Designing ... Now we can extend a comprehensive, end-to-end, digital solution ... strategy, and execution,” said Chuck Miller, president of The ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... LLC ( http://www.trimarkpublications.com ), a global leader in the ... newly published Regenerative Medicine Markets report that ... $3 billion in 2010 and is expected to reach ... to treat injuries and diseases with specially-grown tissues by ...
... YOKOHAMA, Japan, September 1, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
Cached Biology Technology:Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6Medisafe 1 Technologies Announces 1-5 Stock Dividend 2Medisafe 1 Technologies Announces 1-5 Stock Dividend 3Medisafe 1 Technologies Announces 1-5 Stock Dividend 4Medisafe 1 Technologies Announces 1-5 Stock Dividend 5Medisafe 1 Technologies Announces 1-5 Stock Dividend 6
(Date:3/10/2015)... -- Continuing its 167-year history of offering the Best, the ... Eye Scanning Password Authenticator , a device that confirms ... or sensitive data. Employing the same biometric ... device has a small camera that scans and saves ... them into an encrypted ID that cannot be forged ...
(Date:3/10/2015)... March 10, 2015  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the ... smart wallet has been named the "Number One ... Rethink Modern ( http://www.rethinkmodern.com/ ) is ... your home and lifestyle that have a unique function ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... large, multisite trial designed to examine the safety ... to prevent HIV infection has opened to volunteer ... of Allergy and Infectious Diseases (NIAID), part of ... among various research institutions in Africa and the ...
... brain-clogging deposits that cause such disorders as Alzheimer's ... out how to capture and "micromanipulate" the single ... aim is to understand the detailed assembly process ... basic understanding, they said, could lead to approaches ...
Cached Biology News: MetaChip provides quick, efficient toxicity screening of potential drugs 2Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
... and easy to use Ascent ... all members of the Ascent ... a clear and easy-to-follow approach ... user-friendly and highly sophisticated data ...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Biology Products: